Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1990 2
1991 6
1992 5
1993 5
1994 13
1995 6
1996 14
1997 12
1998 18
1999 14
2000 17
2001 14
2002 15
2003 20
2004 13
2005 16
2006 18
2007 9
2008 11
2009 12
2010 11
2011 11
2012 10
2013 11
2014 13
2015 15
2016 13
2017 16
2018 13
2019 10
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

345 results
Results by year
Filters applied: . Clear all
Page 1
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy.
Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, Turkoz A, Kopan R, Schaffer A, Saavedra AP, Wallendorf M, Cornelius LA, Demehri S. Cunningham TJ, et al. J Clin Invest. 2017 Jan 3;127(1):106-116. doi: 10.1172/JCI89820. Epub 2016 Nov 21. J Clin Invest. 2017. PMID: 27869649 Free PMC article. Clinical Trial.
METHODS: The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. ...Four-day application of calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of ac …
METHODS: The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. ...Fou …
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.
Rosenberg AR, Tabacchi M, Ngo KH, Wallendorf M, Rosman IS, Cornelius LA, Demehri S. Rosenberg AR, et al. JCI Insight. 2019 Mar 21;4(6):e125476. doi: 10.1172/jci.insight.125476. eCollection 2019 Mar 21. JCI Insight. 2019. PMID: 30895944 Free PMC article. Clinical Trial.
However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol
However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blind …
Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
Xia L, Li R, Wang Y, Lin Z, Zheng J, Li X, Lu Q, Zhang J, Jin H, Fu L, Zhang X, Liu Y, Yang S, Xiao F, Gao XH. Xia L, et al. Dermatol Ther. 2018 Sep;31(5):e12632. doi: 10.1111/dth.12632. Epub 2018 Sep 25. Dermatol Ther. 2018. PMID: 30253049 Clinical Trial.
To assess the efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment and calcipotriol/betamethasone dipropionate ointment in the treatment of mild-to-moderate patients with psoriasis vulgaris. ...All-trans retinoic acid/ …
To assess the efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment and calcipotrio
A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.
Tyring S, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T, Lee M. Tyring S, et al. Int J Dermatol. 2010 Nov;49(11):1328-33. doi: 10.1111/j.1365-4632.2010.04598.x. Int J Dermatol. 2010. PMID: 20964660 Clinical Trial.
The calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non-Hispanic. ...
The calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment …
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L. Leonardi C, et al. J Drugs Dermatol. 2015 Dec;14(12):1468-77. J Drugs Dermatol. 2015. PMID: 26659941 Clinical Trial.
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes. ...
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) design …
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Koo J, et al. J Dermatolog Treat. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7. J Dermatolog Treat. 2016. PMID: 26444907 Free PMC article. Clinical Trial.
BACKGROUND: An aerosol foam formulation of fixed combination calcipotriene 0.005% (as hydrate; Cal) plus betamethasone dipropionate 0.064% (BD) was developed to improve psoriasis treatment. ...
BACKGROUND: An aerosol foam formulation of fixed combination calcipotriene 0.005% (as hydrate; Cal) plus betamethasone dipropionate 0 …
Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial.
El Taieb MA, Hegazy EM, Ibrahim HM, Osman AB, Abualhamd M. El Taieb MA, et al. Arch Dermatol Res. 2019 Oct;311(8):629-636. doi: 10.1007/s00403-019-01943-8. Epub 2019 Jun 24. Arch Dermatol Res. 2019. PMID: 31236672 Clinical Trial.
The objectives of this study are to compare the efficacy of topical calcipotriol vs narrow band ultraviolet B phototherapy (NB-UVB) in the treatment of alopecia areata and its correlation with serum vitamin D(3) levels. A randomized-controlled trial has been conducted on 6 …
The objectives of this study are to compare the efficacy of topical calcipotriol vs narrow band ultraviolet B phototherapy (NB-UVB) i …
Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo.
Ibrahim ZA, Hassan GF, Elgendy HY, Al-Shenawy HA. Ibrahim ZA, et al. J Cosmet Dermatol. 2019 Apr;18(2):581-588. doi: 10.1111/jocd.12704. Epub 2018 Jul 16. J Cosmet Dermatol. 2019. PMID: 30009490 Clinical Trial.
AIM: To evaluate the efficacy of microneedling with tacrolimus versus its efficacy with calcipotriol plus betamethasone in vitiligo treatment. METHODS: Twenty-five patients having vitiligo were selected and their symmetrical patches were divided into side A (right side) wh …
AIM: To evaluate the efficacy of microneedling with tacrolimus versus its efficacy with calcipotriol plus betamethasone in vitiligo t …
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
White S, Vender R, Thaçi D, Haverkamp C, Naeyaert JM, Foster R, Martinez Escribano JA, Cambazard F, Bibby A. White S, et al. Am J Clin Dermatol. 2006;7(3):177-84. doi: 10.2165/00128071-200607030-00004. Am J Clin Dermatol. 2006. PMID: 16734505 Clinical Trial.
METHODS: Patients with psoriasis were randomized to one of the following three treatment groups: 4 weeks of the two-compound product followed by 8 weeks of calcipotriene cream (calcipotriene cream group); 4 weeks of the two-compound product followed by 8 weeks of …
METHODS: Patients with psoriasis were randomized to one of the following three treatment groups: 4 weeks of the two-compound product followe …
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, Griffiths CE. Paul C, et al. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):119-126. doi: 10.1111/jdv.13859. Epub 2016 Aug 17. J Eur Acad Dermatol Venereol. 2017. PMID: 27531752 Free PMC article. Clinical Trial.
BACKGROUND: Fixed combination calcipotriol 50 mug/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis. ...
BACKGROUND: Fixed combination calcipotriol 50 mug/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment …
345 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page